• FLEXcyte 96

  • FLEXcyte 96

  • FLEXcyte 96

  • FLEXcyte 96


2020 - Integration of mechanical conditioning into a high throughput contractility assay for cardiac safety assessment

 Icon FLEX   FLEXcyte 96 Publication in the Journal of Pharmacological and Toxicological Methods (2020)

Gossmann M., Linder P., Thomas U., Juhasz K., Lemme M., George M., Fertig N., Dragicevic E., Stoelzle-Feix S.


Journal of Pharmacological and Toxicological Methods (2020) doi: 10.1016/j.vascn.2020.106892


Despite increasing acceptance of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) in safety pharmacology, controversy remains about the physiological relevance of existing in vitro models for their mechanical testing. We hypothesize that existing signs of immaturity of the cell models result from an improper mechanical environment. With the presented study, we aimed at validating the newly developed FLEXcyte 96 technology with respect to physiological responses of hiPSC-CMs to pharmacological compounds with known inotropic and/or cardiotoxic effects.

Download here


FLEXcyte 96 Brochure

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.